Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study Comparing GW572016 and Letrozole Versus Letrozole in Subjects With Estrogen/Progesterone Receptor- Positive Advanced or Metastatic Breast Cancer

This study evaluated and compared the efficacy and tolerability of lapatinib and letrozole, with letrozole and placebo in post-menopausal women with hormone receptor positive (ER positive and/or PgR positive) advanced or metastatic breast cancer, who had not received prior therapy for advanced or metastatic disease.

Study Overview

• Status: Completed
• Conditions: Breast Neoplasms
• Intervention / Treatment: Drug: Letrozole; Drug: Placebo; Drug: Lapatinib

Detailed Description

Subjects were randomly assigned to receive either lapatinib (1500 mg once daily orally) with letrozole (2.5 mg once daily orally), or letrozole (2.5 mg once daily orally) with placebo (which matched with lapatinib tablet). Randomization was stratified by site of disease (i.e., soft tissue/visceral disease versus bone only disease) and time since prior adjuvant endocrine therapy (<6 months or ≥ 6 months from discontinuation of adjuvant anti-estrogen therapy (e.g. tamoxifen or raloxifene) or no prior adjuvant antiestrogen therapy). Study therapy was administered daily until disease progression (objective or symptomatic) or withdrawal from therapy (e.g., due to unacceptable toxicity, withdrawal of consent, or other reason). All subjects were to be followed for survival information until death.

On 13 Apr 2015, after the introduction of the Long Term Follow UP (LTFU) phase (per protocol amendment 07), subjects receiving study treatment with lapatinib plus letrozole, or letrozole plus placebo had continued access to this study treatment until the occurrence of one of the following criteria:

• Disease progression (as determined by the Investigator),
• Intercurrent illness that prevented further administration of study treatment
• Drug related AE which was considered by the investigator to warrant permanent discontinuation of study treatment
• The subject decided to withdraw from the study. Investigators collected AEs and/or SAEs related to study participation, until 30 days following study treatment discontinuation. Subjects who were being followed-up for OS but were not taking study medication, were withdrawn from the study.

The study was terminated on 22-Mar-2018 (last subject last visit).

• Study Type: Interventional
• Enrollment (Actual): 1286
• Phase: Phase 3

Contacts and Locations

Study Locations

• Argentina
  • Buenos Aires, Argentina, 1425
    • Novartis Investigative Site
  • Ciudad Autonoma de Buenos Aires, Argentina, C1405BWU
    • Novartis Investigative Site
  • Buenos Aires
    • Capital Federal, Buenos Aires, Argentina, C1426ANZ
      • Novartis Investigative Site
• Australia
  • Australian Capital Territory
    • Garran, Australian Capital Territory, Australia, 2606
      • Novartis Investigative Site
  • Queensland
    • Douglas, Queensland, Australia, 4814
      • Novartis Investigative Site
    • Herston, Queensland, Australia, 4029
      • Novartis Investigative Site
    • Redcliffe, Queensland, Australia, 4020
      • Novartis Investigative Site
  • South Australia
    • Adelaide, South Australia, Australia, 5000
      • Novartis Investigative Site
• Brazil
  • Rio de Janeiro, Brazil, 20560-120
    • Novartis Investigative Site
  • Bahía
    • Salvador, Bahía, Brazil, 41825-010
      • Novartis Investigative Site
• Bulgaria
  • Plovdiv, Bulgaria, 4000
    • Novartis Investigative Site
  • Sofia, Bulgaria, 1527
    • Novartis Investigative Site
  • Sofia, Bulgaria, 1756
    • Novartis Investigative Site
• Canada
  • Quebec, Canada, G1S 4L8
    • Novartis Investigative Site
  • Manitoba
    • Winnipeg, Manitoba, Canada, R2H 2A6
      • Novartis Investigative Site
  • Ontario
    • London, Ontario, Canada, N6A 4L6
      • Novartis Investigative Site
    • Mississauga, Ontario, Canada, L5B 1B8
      • Novartis Investigative Site
    • Oshawa, Ontario, Canada, L1G 2B9
      • Novartis Investigative Site
    • Sudbury, Ontario, Canada, P3E 5J1
      • Novartis Investigative Site
    • Toronto, Ontario, Canada, M6R 1B5
      • Novartis Investigative Site
  • Quebec
    • Montreal, Quebec, Canada, H3T 1E2
      • Novartis Investigative Site
    • Montreal, Quebec, Canada, H1T 2M4
      • Novartis Investigative Site
    • Montreal, Quebec, Canada, H2L 4M1
      • Novartis Investigative Site
    • Montreal, Quebec, Canada, H4J 1C5
      • Novartis Investigative Site
    • Sherbrooke, Quebec, Canada, J1H 5N4
      • Novartis Investigative Site
• Chile
  • Región Metro De Santiago
    • Santiago, Región Metro De Santiago, Chile, 7500921
      • Novartis Investigative Site
    • Santiago, Región Metro De Santiago, Chile, 7591046
      • Novartis Investigative Site
• Colombia
  • Bogota, Colombia
    • Novartis Investigative Site
• Croatia
  • Osijek, Croatia, 31000
    • Novartis Investigative Site
  • Pula, Croatia, 52100
    • Novartis Investigative Site
  • Split, Croatia, 21000
    • Novartis Investigative Site
• Czechia
  • Brno, Czechia, 656 53
    • Novartis Investigative Site
  • Ceske Budejovice, Czechia, 370 87
    • Novartis Investigative Site
  • Praha 8, Czechia, 180 00
    • Novartis Investigative Site
• Denmark
  • Aalborg, Denmark, 9000
    • Novartis Investigative Site
  • Hillerod, Denmark, 3400
    • Novartis Investigative Site
  • Koebenhavn Oe, Denmark, 2100
    • Novartis Investigative Site
  • Naestved, Denmark, 4700
    • Novartis Investigative Site
  • Odense C, Denmark, 5000
    • Novartis Investigative Site
  • Roskilde, Denmark, 4000
    • Novartis Investigative Site
  • Vejle, Denmark, 7100
    • Novartis Investigative Site
• France
  • Angers Cedex 01, France, 49033
    • Novartis Investigative Site
  • Besancon, France, 25030
    • Novartis Investigative Site
  • Grenoble Cedex 9, France, 38043
    • Novartis Investigative Site
  • Lille Cedex, France, 59020
    • Novartis Investigative Site
  • Montpellier, France, 34298
    • Novartis Investigative Site
  • Paris Cedex 5, France, 75248
    • Novartis Investigative Site
  • Pierre Benite Cedex, France, 69495
    • Novartis Investigative Site
  • Toulouse Cedex9, France, 31059
    • Novartis Investigative Site
  • Villejuif Cedex, France, 94805
    • Novartis Investigative Site
• Germany
  • Berlin, Germany, 10117
    • Novartis Investigative Site
  • Berlin, Germany, 10317
    • Novartis Investigative Site
  • Berlin, Germany, 14195
    • Novartis Investigative Site
  • Berlin, Germany, 12200
    • Novartis Investigative Site
  • Hamburg, Germany, 20259
    • Novartis Investigative Site
  • Hamburg, Germany, 22081
    • Novartis Investigative Site
  • Hamburg, Germany, 22457
    • Novartis Investigative Site
  • Hamburg, Germany, 20095
    • Novartis Investigative Site
  • Hamburg, Germany, 22767
    • Novartis Investigative Site
  • Baden-Wuerttemberg
    • Aalen, Baden-Wuerttemberg, Germany, 73428
      • Novartis Investigative Site
    • Freiburg, Baden-Wuerttemberg, Germany, 79106
      • Novartis Investigative Site
    • Heidelberg, Baden-Wuerttemberg, Germany, 69115
      • Novartis Investigative Site
    • Heidenheim, Baden-Wuerttemberg, Germany, 89518
      • Novartis Investigative Site
    • Schwetzingen, Baden-Wuerttemberg, Germany, 68723
      • Novartis Investigative Site
    • Stuttgart, Baden-Wuerttemberg, Germany, 70174
      • Novartis Investigative Site
    • Ulm, Baden-Wuerttemberg, Germany, 89075
      • Novartis Investigative Site
  • Bayern
    • Augsburg, Bayern, Germany, 86150
      • Novartis Investigative Site
    • Bayreuth, Bayern, Germany, 95445
      • Novartis Investigative Site
    • Erlangen, Bayern, Germany, 91054
      • Novartis Investigative Site
    • Muenchen, Bayern, Germany, 80335
      • Novartis Investigative Site
    • Muenchen, Bayern, Germany, 80637
      • Novartis Investigative Site
    • Muenchen, Bayern, Germany, 81377
      • Novartis Investigative Site
    • Regensburg, Bayern, Germany, 93049
      • Novartis Investigative Site
    • Rehling, Bayern, Germany, 86508
      • Novartis Investigative Site
    • Rosenheim, Bayern, Germany, 83002
      • Novartis Investigative Site
  • Hessen
    • Frankfurt, Hessen, Germany, 60596
      • Novartis Investigative Site
    • Frankfurt am Main, Hessen, Germany, 60590
      • Novartis Investigative Site
    • Wiesbaden, Hessen, Germany, 65199
      • Novartis Investigative Site
    • Wiesbaden, Hessen, Germany, 65191
      • Novartis Investigative Site
  • Niedersachsen
    • Goslar, Niedersachsen, Germany, 38642
      • Novartis Investigative Site
    • Leer, Niedersachsen, Germany, 26789
      • Novartis Investigative Site
  • Nordrhein-Westfalen
    • Bonn, Nordrhein-Westfalen, Germany, 53127
      • Novartis Investigative Site
    • Coesfeld, Nordrhein-Westfalen, Germany, 48653
      • Novartis Investigative Site
    • Duesseldorf, Nordrhein-Westfalen, Germany, 40217
      • Novartis Investigative Site
    • Ibbenbueren, Nordrhein-Westfalen, Germany, 49477
      • Novartis Investigative Site
    • Muenster, Nordrhein-Westfalen, Germany, 48149
      • Novartis Investigative Site
    • Troisdorf, Nordrhein-Westfalen, Germany, 53840
      • Novartis Investigative Site
    • Velbert, Nordrhein-Westfalen, Germany, 42551
      • Novartis Investigative Site
  • Rheinland-Pfalz
    • Altenkirchen, Rheinland-Pfalz, Germany, 57610
      • Novartis Investigative Site
  • Sachsen
    • Chemnitz, Sachsen, Germany, 09009
      • Novartis Investigative Site
    • Dresden, Sachsen, Germany, 01219
      • Novartis Investigative Site
  • Schleswig-Holstein
    • Kiel, Schleswig-Holstein, Germany, 24105
      • Novartis Investigative Site
    • Kiel, Schleswig-Holstein, Germany, 24103
      • Novartis Investigative Site
    • Pinneberg, Schleswig-Holstein, Germany, 25421
      • Novartis Investigative Site
  • Thueringen
    • Jena, Thueringen, Germany, 07743
      • Novartis Investigative Site
• Hungary
  • Budapest, Hungary, 1032
    • Novartis Investigative Site
  • Budapest, Hungary, 1096
    • Novartis Investigative Site
  • Budapest, Hungary, 1088
    • Novartis Investigative Site
  • Kecskemet, Hungary, 6000
    • Novartis Investigative Site
  • Kistarcsa, Hungary, 2143
    • Novartis Investigative Site
  • Szeged, Hungary, 6720
    • Novartis Investigative Site
  • Tatabanya, Hungary, 2800
    • Novartis Investigative Site
• Ireland
  • Cork, Ireland
    • Novartis Investigative Site
  • Dooradoyle, Ireland
    • Novartis Investigative Site
  • Dublin, Ireland, 8
    • Novartis Investigative Site
  • Dublin, Ireland, 9
    • Novartis Investigative Site
  • Dublin, Ireland, 4
    • Novartis Investigative Site
  • Galway, Ireland
    • Novartis Investigative Site
  • Tallaght, Dublin, Ireland, 24
    • Novartis Investigative Site
  • Wilton, Cork, Ireland
    • Novartis Investigative Site
• Italy
  • Emilia-Romagna
    • Bologna, Emilia-Romagna, Italy, 40138
      • Novartis Investigative Site
    • Parma, Emilia-Romagna, Italy, 43100
      • Novartis Investigative Site
  • Lazio
    • Roma, Lazio, Italy, 00152
      • Novartis Investigative Site
    • Roma, Lazio, Italy, 00133
      • Novartis Investigative Site
  • Liguria
    • Genova, Liguria, Italy, 16132
      • Novartis Investigative Site
    • Genova, Liguria, Italy, 16128
      • Novartis Investigative Site
  • Lombardia
    • Crema, Lombardia, Italy, 26013
      • Novartis Investigative Site
    • Milano, Lombardia, Italy, 20162
      • Novartis Investigative Site
• Korea, Republic of
  • Gyeonggi-do, Korea, Republic of, 411-769
    • Novartis Investigative Site
  • Seodaemun-gu, Seoul, Korea, Republic of, 03722
    • Novartis Investigative Site
  • Seoul, Korea, Republic of, 135-710
    • Novartis Investigative Site
• Mexico
  • Colima, Mexico, 28010
    • Novartis Investigative Site
  • Durango, Mexico, 34000
    • Novartis Investigative Site
  • Durango, Mexico, 34079
    • Novartis Investigative Site
  • Mexico, D.F., Mexico, 14050
    • Novartis Investigative Site
  • Guerrero
    • Acapulco, Guerrero, Mexico, 39670
      • Novartis Investigative Site
• Netherlands
  • Amersfoort, Netherlands, 3813 TZ
    • Novartis Investigative Site
  • Delft, Netherlands, 2625 AD
    • Novartis Investigative Site
  • Den Haag, Netherlands, 2512 VA
    • Novartis Investigative Site
  • Den Haag, Netherlands, 2545 CH
    • Novartis Investigative Site
  • Doetinchem, Netherlands, 7009 BL
    • Novartis Investigative Site
  • Eindhoven, Netherlands, 5623 EJ
    • Novartis Investigative Site
  • Heerlen, Netherlands, 6419 PC
    • Novartis Investigative Site
  • Leidschendam, Netherlands, 2262 BA
    • Novartis Investigative Site
  • Maastricht, Netherlands, 6229 HX
    • Novartis Investigative Site
  • Nieuwegein, Netherlands, 3435 CM
    • Novartis Investigative Site
  • Sittard-geleen, Netherlands, 6162 BG
    • Novartis Investigative Site
  • Utrecht, Netherlands, 3584 CX
    • Novartis Investigative Site
  • Utrecht, Netherlands, 3582 KE
    • Novartis Investigative Site
• New Zealand
  • Christchurch, New Zealand, 8001
    • Novartis Investigative Site
• Pakistan
  • Lahore, Pakistan
    • Novartis Investigative Site
  • Lahore, Pakistan, 54000
    • Novartis Investigative Site
  • Rawalpindi, Pakistan, 46000
    • Novartis Investigative Site
• Peru
  • Callao, Peru, Callao 2
    • Novartis Investigative Site
  • Lima, Peru, Lima 34
    • Novartis Investigative Site
• Poland
  • Bydogoszcz, Poland, 85-796
    • Novartis Investigative Site
  • Krakow, Poland, 31-115
    • Novartis Investigative Site
  • Poznan, Poland, 61-866
    • Novartis Investigative Site
  • Warszawa, Poland, 02-781
    • Novartis Investigative Site
  • Wroclaw, Poland, 53-413
    • Novartis Investigative Site
• Russian Federation
  • Moscow, Russian Federation, 115 478
    • Novartis Investigative Site
  • Moscow, Russian Federation, 107005
    • Novartis Investigative Site
  • St. Petersburg, Russian Federation, 197758
    • Novartis Investigative Site
  • St. Petersburg, Russian Federation, 197022
    • Novartis Investigative Site
• South Africa
  • Capital Park, South Africa, 0002
    • Novartis Investigative Site
  • Panorama, South Africa, 7500
    • Novartis Investigative Site
  • Parktown, South Africa, 2193
    • Novartis Investigative Site
  • Port Elizabeth, South Africa, 6001
    • Novartis Investigative Site
• Spain
  • Alcala De Henares (Madrid), Spain
    • Novartis Investigative Site
  • Badalona, Spain, 08916
    • Novartis Investigative Site
  • Barcelona, Spain, 08036
    • Novartis Investigative Site
  • Elche, Spain, 03203
    • Novartis Investigative Site
  • Girona, Spain, 17007
    • Novartis Investigative Site
  • Leganes, Madrid, Spain, 28911
    • Novartis Investigative Site
  • Madrid, Spain, 28041
    • Novartis Investigative Site
  • Madrid, Spain, 28034
    • Novartis Investigative Site
  • Madrid, Spain, 28007
    • Novartis Investigative Site
  • Madrid, Spain, 28040
    • Novartis Investigative Site
  • Madrid, Spain, 28035
    • Novartis Investigative Site
  • Malaga, Spain, 29010
    • Novartis Investigative Site
  • Mostoles, Spain, 28935
    • Novartis Investigative Site
  • Oviedo, Spain, 33006
    • Novartis Investigative Site
  • Palma de Mallorca, Spain, 07010
    • Novartis Investigative Site
  • San Sebastian, Spain, 20014
    • Novartis Investigative Site
  • Valencia, Spain, 46010
    • Novartis Investigative Site
  • Vigo ( Pontevedra), Spain, 36204
    • Novartis Investigative Site
  • Zaragoza, Spain, 50009
    • Novartis Investigative Site
• Tunisia
  • Sfax, Tunisia, 3000
    • Novartis Investigative Site
  • Sousse, Tunisia, 4000
    • Novartis Investigative Site
  • Tunis, Tunisia, 1007
    • Novartis Investigative Site
  • Tunis, Tunisia, 1004
    • Novartis Investigative Site
• Turkey
  • Ankara, Turkey, 06100
    • Novartis Investigative Site
  • Istanbul, Turkey
    • Novartis Investigative Site
  • Istanbul, Turkey, 34865
    • Novartis Investigative Site
• United Kingdom
  • Huddersfield, United Kingdom, HD3 3EA
    • Novartis Investigative Site
  • London, United Kingdom, SW3 6JJ
    • Novartis Investigative Site
  • London, United Kingdom, NW3 2QG
    • Novartis Investigative Site
  • London, United Kingdom, SW17 0QT
    • Novartis Investigative Site
  • Sheffield, United Kingdom, S10 2SJ
    • Novartis Investigative Site
  • Essex
    • Chelmsford, Essex, United Kingdom, CM1 7ET
      • Novartis Investigative Site
  • Lancashire
    • Manchester, Lancashire, United Kingdom, M20 4BX
      • Novartis Investigative Site
  • Middlesex
    • Northwood, Middlesex, United Kingdom, HA6 2RN
      • Novartis Investigative Site
  • Surrey
    • Sutton, Surrey, United Kingdom, SM2 5PT
      • Novartis Investigative Site
  • West Midlands
    • Birmingham, West Midlands, United Kingdom, B18 7QH
      • Novartis Investigative Site
• United States
  • Arizona
    • Tucson, Arizona, United States, 85715
      • Novartis Investigative Site
  • Arkansas
    • Hot Springs, Arkansas, United States, 71913
      • Novartis Investigative Site
    • Jonesboro, Arkansas, United States, 72401
      • Novartis Investigative Site
  • California
    • Alhambra, California, United States, 91801
      • Novartis Investigative Site
    • Bakersfield, California, United States, 93309
      • Novartis Investigative Site
    • Duarte, California, United States, 91010
      • Novartis Investigative Site
    • Fountain Valley, California, United States, 92708
      • Novartis Investigative Site
    • Fresno, California, United States, 93710
      • Novartis Investigative Site
    • Fullerton, California, United States, 92835
      • Novartis Investigative Site
    • La Jolla, California, United States, 92093-0987
      • Novartis Investigative Site
    • Long Beach, California, United States, 90813
      • Novartis Investigative Site
    • Los Angeles, California, United States, 90095
      • Novartis Investigative Site
    • Montebello, California, United States, 90640
      • Novartis Investigative Site
    • Northridge, California, United States, 91325
      • Novartis Investigative Site
    • Oxnard, California, United States, 93030
      • Novartis Investigative Site
    • Pleasant Hill, California, United States, 94523
      • Novartis Investigative Site
    • Porterville, California, United States, 93257
      • Novartis Investigative Site
    • Redondo Beach, California, United States, 90277
      • Novartis Investigative Site
    • San Diego, California, United States, 92120
      • Novartis Investigative Site
    • Santa Barbara, California, United States, 93105
      • Novartis Investigative Site
    • Santa Maria, California, United States, 93454
      • Novartis Investigative Site
    • Vallejo, California, United States, 94589
      • Novartis Investigative Site
    • Vista, California, United States, 92081
      • Novartis Investigative Site
  • Colorado
    • Aurora, Colorado, United States, 80045
      • Novartis Investigative Site
    • Denver, Colorado, United States, 80220
      • Novartis Investigative Site
    • Longmont, Colorado, United States, 80501
      • Novartis Investigative Site
    • Wheat Ridge, Colorado, United States, 80033
      • Novartis Investigative Site
  • Connecticut
    • New Haven, Connecticut, United States, 06520
      • Novartis Investigative Site
  • Florida
    • Boca Raton, Florida, United States, 33486
      • Novartis Investigative Site
    • Boca Raton, Florida, United States, 33428
      • Novartis Investigative Site
    • Gainesville, Florida, United States, 32610
      • Novartis Investigative Site
    • Gainesville, Florida, United States, 32605
      • Novartis Investigative Site
    • Hollywood, Florida, United States, 33021
      • Novartis Investigative Site
    • Lakeland, Florida, United States, 33805
      • Novartis Investigative Site
    • Miami, Florida, United States, 33136
      • Novartis Investigative Site
    • Orlando, Florida, United States, 32804
      • Novartis Investigative Site
    • Port Saint Lucie, Florida, United States, 34952
      • Novartis Investigative Site
    • West Palm Beach, Florida, United States, 33401
      • Novartis Investigative Site
  • Georgia
    • Atlanta, Georgia, United States, 30341
      • Novartis Investigative Site
    • Marietta, Georgia, United States, 30060
      • Novartis Investigative Site
    • Savannah, Georgia, United States, 31406
      • Novartis Investigative Site
  • Illinois
    • Peoria, Illinois, United States, 61615
      • Novartis Investigative Site
    • Skokie, Illinois, United States, 60076
      • Novartis Investigative Site
  • Indiana
    • Indianapolis, Indiana, United States, 46202
      • Novartis Investigative Site
  • Iowa
    • Bettendorf, Iowa, United States, 52722
      • Novartis Investigative Site
  • Kentucky
    • Louisville, Kentucky, United States, 40202
      • Novartis Investigative Site
  • Louisiana
    • Metairie, Louisiana, United States, 70006
      • Novartis Investigative Site
    • New Orleans, Louisiana, United States, 70121
      • Novartis Investigative Site
  • Massachusetts
    • Worcester, Massachusetts, United States, 01608
      • Novartis Investigative Site
  • Minnesota
    • Duluth, Minnesota, United States, 55805
      • Novartis Investigative Site
    • Minneapolis, Minnesota, United States, 55407-3799
      • Novartis Investigative Site
    • Robbinsdale, Minnesota, United States, 55422
      • Novartis Investigative Site
    • Saint Louis Park, Minnesota, United States, 55426
      • Novartis Investigative Site
  • Missouri
    • Saint Charles, Missouri, United States, 63304
      • Novartis Investigative Site
    • Saint Louis, Missouri, United States, 63141
      • Novartis Investigative Site
  • Nebraska
    • Omaha, Nebraska, United States, 68114
      • Novartis Investigative Site
  • Nevada
    • Las Vegas, Nevada, United States, 89169
      • Novartis Investigative Site
  • New Jersey
    • Voorhees, New Jersey, United States, 08043
      • Novartis Investigative Site
  • New Mexico
    • Santa Fe, New Mexico, United States, 87505
      • Novartis Investigative Site
  • New York
    • Manhasset, New York, United States, 11030
      • Novartis Investigative Site
    • Rochester, New York, United States, 14623
      • Novartis Investigative Site
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599-7305
      • Novartis Investigative Site
    • Greenville, North Carolina, United States, 27834
      • Novartis Investigative Site
  • North Dakota
    • Fargo, North Dakota, United States, 58103
      • Novartis Investigative Site
  • Ohio
    • Canton, Ohio, United States, 44718
      • Novartis Investigative Site
  • Pennsylvania
    • Hershey, Pennsylvania, United States, 17033
      • Novartis Investigative Site
    • Philadelphia, Pennsylvania, United States, 19111
      • Novartis Investigative Site
    • Pittsburgh, Pennsylvania, United States, 15212
      • Novartis Investigative Site
  • South Carolina
    • West Columbia, South Carolina, United States, 29210
      • Novartis Investigative Site
  • Tennessee
    • Germantown, Tennessee, United States, 38138
      • Novartis Investigative Site
    • Knoxville, Tennessee, United States, 37916
      • Novartis Investigative Site
  • Texas
    • Amarillo, Texas, United States, 79106
      • Novartis Investigative Site
    • Dallas, Texas, United States, 75246
      • Novartis Investigative Site
    • Dallas, Texas, United States, 75390-9113
      • Novartis Investigative Site
    • Houston, Texas, United States, 77025
      • Novartis Investigative Site
    • Irving, Texas, United States, 75061
      • Novartis Investigative Site
  • Utah
    • Ogden, Utah, United States, 84403
      • Novartis Investigative Site
    • Salt Lake City, Utah, United States, 84106
      • Novartis Investigative Site
  • Vermont
    • Burlington, Vermont, United States, 05401
      • Novartis Investigative Site
  • Virginia
    • Danville, Virginia, United States, 24541
      • Novartis Investigative Site
    • Richmond, Virginia, United States, 23230
      • Novartis Investigative Site
  • Washington
    • Seattle, Washington, United States, 98104
      • Novartis Investigative Site
    • Tacoma, Washington, United States, 98405
      • Novartis Investigative Site
  • West Virginia
    • Charleston, West Virginia, United States, 25304
      • Novartis Investigative Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Key inclusion criteria

1. Signed informed consent;

2. Subjects with histologically confirmed invasive breast cancer with stage IV disease at primary diagnosis or at relapse after curative-intent surgery;

   • Subjects with either measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST).
   • If the disease was restricted to a solitary lesion, its neoplastic nature was confirmed by cytology or histology.
3. Tumors that were ER+ and/or PgR+;
4. Post-menopausal female subjects ≥ 18 years of age.
5. ECOG Performance Status of 0 or 1;
6. Subjects who had archived tumor tissue available to compare tumor response with intra-tumoral expression of ErbB1 and ErbB2.
7. Adjuvant therapy with an aromatase inhibitor and / or trastuzumab was allowed; however, treatment was to stop more than 1 year prior (>12 months) to the first dose of randomized therapy.
8. Subjects must have ended hormonal replacement therapy (HRT) at least 1 month (30 days) prior to receiving the first dose of randomized therapy.

Key exclusion criteria:

1. Pre-menopausal, pregnant, or lactating;
2. Received prior chemotherapy, hormonal therapy, immunotherapy, biologic therapy, or anti-ErbB1/ErbB2 therapy for advanced or metastatic disease;
3. Bisphosphonate therapy for bone metastases was allowed; however, treatment was to be initiated prior to the first dose of randomized therapy. Prophylactic use of bisphosphonates in subjects without bone disease, except for the treatment of osteoporosis, was not permitted;
4. Used an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of randomized therapy (lapatinib or placebo);
5. Subjects with known history of/clinical evidence of CNS metastases or leptomeningeal carcinomatosis; and / or subjects on concurrent anti-cancer therapies other than letrozole; and / or who have not recovered from toxicities related to prior adjuvant therapy (surgery, radiotherapy, chemotherapy etc.)
6. Subjects with active or uncontrolled infection and/ or with history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo + Letrozole 2.5 mg; Letrozole (2.5 mg once daily orally) with Placebo (which matched with Lapatinib tablet)	Drug: Letrozole; 2.5 mg orally once a day; Drug: Placebo; Placebo (which matched with lapatinib tablet)
Experimental: Lapatinib 1500 mg + Letrozole 2.5 mg; Lapatinib (1500 mg once daily orally) with Letrozole (2.5 mg once daily orally)	Drug: Letrozole; 2.5 mg orally once a day; Drug: Lapatinib; 1500 mg orally once a day; Other Names: GW572016

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Progression Free Survival (PFS) in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced or Metastatic Breast Cancer as Assessed by the Investigator	PFS is defined as the time from randomization until the earliest date of disease progression (PD) or death due to any cause, if sooner. The date of documented PD is defined as the date of radiological PD as assessed by the investigator based on imaging data and also by the clinical assessment of symptomatic progression. Per Response Evaluation Criteria in Solid Tumors (RECIST 1.0), PD is defined as a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as a reference the smallest sum LD recorded since the treatment started, or the appearance of 1 or more new lesions.	From the date of randomization until the date of the first documented progression or date of death from any cause, whichever came first, assessed for up to 46 months
Progression Free Survival (PFS) of Participants in the HER2-Positive Population as Assessed by the Investigator	PFS is defined as the time from randomization until the earliest date of disease progression or death due to any cause, if sooner. The date of documented disease progression is defined as the date of radiological disease progression as assessed by the investigator based on imaging data and also by the clinical assessment of symptomatic progression. Per RECIST 1.0, disease progression is defined as a 20% increase in the sum of the LD of target lesions, taking as a reference the smallest sum LD recorded since the treatment started, or the appearance of 1 or more new lesions.	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 46 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With PFS in the Intent-To-Treat (ITT) Population as Assessed by the Investigator	PFS is defined as the time from randomization until the earliest date of disease progression or death due to any cause, if sooner. The date of documented disease progression is defined as the date of radiological disease progression as assessed by the investigator based on imaging data and also by the clinical assessment of symptomatic progression. Per RECIST 1.0, disease progression is defined as a 20% increase in the sum of the LD of target lesions, taking as a reference the smallest sum LD recorded since the treatment started, or the appearance of 1 or more new lesions.	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 46 months
PFS in Participants in the ITT Population as Assessed by the Investigator	PFS is defined as the time from randomization until the earliest date of disease progression or death due to any cause, if sooner. The date of documented disease progression is defined as the date of radiological disease progression as assessed by the investigator based on imaging data and also by the clinical assessment of symptomatic progression. Per RECIST 1.0, disease progression is defined as a 20% increase in the sum of the LD of target lesions, taking as a reference the smallest sum LD recorded since the treatment started, or the appearance of 1 or more new lesions.	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 46 months
Overall Survival in the HER2-Positive Population	Overall survival was defined as the time from randomization until death due to any cause.	From date of randomization until date of death due to any cause, assessed up to 46 months
Overall Tumor Response (OR) for Participants With Measurable and Non-measurable Disease, Including Bone Scans, in the HER2-Positive Population as Assessed by the Investigator	OR is defined as the percentage of participants achieving either a confirmed complete response (CR) or partial response (PR). Response was assessed via Response Evaluation criteria in Solid Tumors (RECIST). The percentage of participants with response was calculated by using the formula: 100 * (number of participants with CR + number of participants with PR)/total number of participants. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as a reference the baseline sum LD.	Up to 46 months
Number of Participants With Overall Tumor Response (OR) by Stratification Factors With Measurable Disease, Including Bone Scans, in the HER2-Positive Population as Assessed by the Investigator	Participants were stratified based on site of disease at screening (SDS) (soft tissue or visceral or bone-only disease) and prior adjuvant endocrine therapy (PAET) (discontinuation interval [DI] =>6 months or DI <6 months). OR is defined as the number of participants achieving either a confirmed CR or PR. Response was assessed via RECIST. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of the LD of target lesions, taking as a reference the baseline sum LD. DI is defined as the time period from stopping the PEAT to the randomization date.	Up to 46 months
Clinical Benefit (CB) in the HER2-Positive Population as Assessed by the Investigator	CB is defined as the percentage of participants with evidence of confirmed CR, PR, or stable disease (SD) for at least 6 months. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of the LD of target lesions, taking as a reference the baseline sum LD. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the baseline measurement.	Up to 46 months
Number of Participants With the Indicated Best Response From the Participants With Measurable and Non-measurable Disease, Including Bone Scans, in the HER2-Positive Population as Assessed by the Investigator.	CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as a reference the smallest sum LD since the baseline measurement. The best overall response is defined as the best response recorded from the start of treatment until disease progression/recurrence. PD: presence of target lesions, non-target lesions, and/or new lesions.	Up to 46 months
Number of Participants With the Indicated Best Response From the Participants With Measurable and Non-measurable Disease, Including Bone Scans, in the ITT Population as Assessed by the Investigator.	CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as a reference the smallest sum LD since the baseline measurement. The best overall response is defined as the best response recorded from the start of treatment until disease progression/recurrence. PD: presence of target lesions, non-target lesions, and/or new lesions.	Up to 46 months
Number of Participants With the Indicated Time to Response for CR or PR in the HER2-Positive Population as Assessed by the Investigator	Time to response is defined as the time from randomization until the first documented evidence of CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sume of the LD of target lesions, taking as reference the baseline sum LD) (whichever status was recorded first). The assessments of CR or PR required confirmation using bone scans.	Up to 46 months
Duration of Response for the Participants With CR or PR in the HER2-Positive Population as Assessed by the Investigator	Duration of response is defined as the time from the first documented evidence of CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of the LD of target lesions, taking as a reference the baseline sum LD) until the first documented sign of disease progression or death due to any cause. The assessments of CR or PR required confirmation using bone scans.	Up to 46 months
Number of Participants With Evidence of Brain Metastases in the HER2-Positive Population	The confirmation criteria for the evidence of brain metastases was the incidence of lesions occurring within any part of the central nervous system (CNS) as evidenced by radiological scans. Metastases are defined as the spread of cancer from one part of the body to another.	Up to 46 months
Time to Progression (TTP) for the HER2-Positive Population as Assessed by the Investigator	TTP is defined as the interval between the date of randomization and the earliest date of disease progression or death due to breast cancer. Disease progression was based on the assessments by the Investigator.	Up to 46 months
Overall Survival in the ITT Population	Overall survival was defined as the time from randomization until death due to any cause.	From date of randomization until date of death due to any cause, assessed up to 46 months
Overall Tumor Response (OR) for Participants With Measurable and Non-measurable Disease, Including Bone Scans, in the ITT Population as Assessed by the Investigator	OR is defined as the percentage of participants achieving either a confirmed complete response (CR) or partial response (PR). Response was assessed via Response Evaluation criteria in Solid Tumors (RECIST). The percentage of participants with response was calculated by using the formula: 100 * (number of participants with CR + number of participants with PR)/total number of participants. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as a reference the baseline sum LD.	Up to 46 months
Number of Participants With Overall Tumor Response (OR) by Stratification Factors With Measurable Disease, Including Bone Scans, in the ITT Population as Assessed by the Investigator	Participants were stratified based on site of disease at screening (SDS) (soft tissue or visceral or bone-only disease) and prior adjuvant endocrine therapy (PAET) (discontinuation interval [DI] =>6 months or DI <6 months). OR is defined as the number of participants achieving either a confirmed CR or PR. Response was assessed via RECIST. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of the LD of target lesions, taking as a reference the baseline sum LD. DI is defined as the time period from stopping the PEAT and the randomization date.	Up to 46 months
Clinical Benefit (CB) in the ITT Population as Assessed by the Investigator	CB is defined as the percentage of participants with evidence of confirmed CR, PR, or stable disease (SD) for at least 6 months. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of the LD of target lesions, taking as a reference the baseline sum LD. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the baseline measurement.	Up to 46 months
Number of Participants With the Indicated Time to Response for CR or PR in the ITT Population as Assessed by the Investigator	Time to response is defined as the time from randomization until the first documented evidence of CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sume of the LD of target lesions, taking as reference the baseline sum LD) (whichever status was recorded first). The assessments of CR or PR required confirmation using bone scans.	Up to 46 months
Duration of Response for the Participants With CR or PR in the ITT Population as Assessed by the Investigator	Duration of response is defined as the time from the first documented evidence of CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of the LD of target lesions, taking as a reference the baseline sum LD) until the first documented sign of disease progression or death due to any cause. The assessments of CR or PR required confirmation using bone scans.	Up to 46 months
Number of Participants With Evidence of Brain Metastases From the ITT Population	The confirmation criteria for the evidence of brain metastases was the incidence of lesions occurring within any part of the central nervous system (CNS) as evidenced by radiological scans. Metastases are defined as the spread of cancer from one part of the body to another.	Up to 46 months
TTP for Participants From the ITT Population as Assessed by the Investigator	TTP is defined as the interval between the date of randomization and the earliest date of disease progression or death due to breast cancer. Disease progression was based on the assessments by the Investigator.	Up to 46 months
Number of Participants Completing the Functional Assessment of Cancer Therapy-breast (FACT-B) Questionnaire at the Scheduled Visits	Quality of Life (QOL) was assessed using the FACT-B questionnaire, which was a 37-item (27 general and 10 breast cancer-specific questions) self-reporting instrument consisting of 5 dimensions: physical-, social/family-, emotional-, functional-well being, and a breast cancer subscale. Higher scores on the FACT-B scales (each ranging from 0 [not at all] to 4 [very much]) indicate a higher QOL. The score is transformed for FACT-B and results in a total score ranging from 0 to 144. Complete: completing at least 1 question from FACT-B.	Day 1 (baseline) visit; Week 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192 visits; conclusion/withdrawal visit
Adjusted Mean Change From Baseline for the FACT-B Total Score Using Observed Data	Quality of Life (QOL) was assessed using the FACT-B questionnaire, which is a 37-item (27 general and 10 breast cancer-specific questions) self-reporting instrument consisting of 5 dimensions: physical-, social/family-, emotional-, functional-well being, and a breast cancer subscale. Higher scores on the FACT-B scales indicate a higher QOL; each ranging from 0 (not at all) to 4 (very much). The score is transformed for FACT-B and results in a total score ranging from 0 to 144. The FACT-B is designed to measure multidimensional QOL in participants with breast cancer.	Week 12, 24, 36, and 48 visits; conclusion/withdrawal visit
Adjusted Mean Change From Baseline for the Functional Assessment of Cancer Therapy-General (FACT-G) Score Using Observed Data	FACT-G is a subscale of the FACT-B QOL questionnaire and consists of 27 questions grouped into 4 domains that measure a participant's physical, functional, social and family, and emotional well-being. FACT-G is assessed on a five-point Likert-type scale, with scores ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). The total score is calculated as the sum of the item scores on the subscale; the total ranges from 0 to 108, with higher score indicating a better quality of life.	Week 12, 24, 36, and 48 visits; conclusion/withdrawal visit
Adjusted Mean Change From Baseline for the Trial Outcome Index (TOI) Score Using Observed Data	The TOI score is the sum of the physical well-being, functional well-being, and breast cancer unweighted subscale scores. The total TOI score ranges from 0 to 92, with higher scores representing a better quality of life.	Week 12, 24, 36, and 48 visits; conclusion/withdrawal visit
Number of Participants Classified as QOL Responders Based on the FACT-B, FACT-G, and TOI Total Scores	A minimally important difference (MID) is the smallest difference in a score for a measure of QOL that corresponds to a difference in function or clinical course. Responders are defined as participants with an MID => 8 for the FACT-B score, and an MID =>6 for the FACT-G and TOI scores.	Up to 46 months
Number of Participants With Clinical Benefit Categorized by HER2 Fluorescence in Situ Hybridization (FISH) Status	Clinical benefit: participants with CR, PR, or SD for =>6-month period. FISH testing measures the amount of the HER2 gene in each cell. This gene is responsible for the overproduction of the HER2 protein. FISH-positive: excessive amounts of the gene are present; FISH-negative: normal levels of the gene are present.	Up to 46 months
Number of Participants With Clinical Benefit Categorized by HER2 ImmunoHistoChemistry (IHC) Intensity	IHC is a commonly used test to assess the amount of the HER2 receptor protein on the surface of the cancer cells. The IHC test results in a score of 0 to 3+, which indicates the amount of HER2 receptor protein on the cells in a sample of breast cancer tissue. Tissue scores of 0 to 1+ indicate HER2 negativity; scores of 2+ and 3+ indicate HER2 positivity. Clinical benefit is defined as participants with CR, PR, or SD for =>6-month period.	Up to 46 months
Number of Participants With Response in Participants With Baseline Serum HER2 Extracellular Domain (ECD) Baseline Values Greater Than 15 Nanograms Per Milliliter (ng/mL) and 15 ng/mL or Lower	The HER2 ECD is a glycoprotein that can be shed from the cell surface into the blood of normal individuals and can be elevated in different pathologic conditions. The serum HER2 ECD level generally reflects the tissue HER2 status. The HER2 ECD is quantified in serum with an enzyme-linked immunosorbent assay (ELISA). Non-Evaluable (NE): any participant who could not be classified as CR, PR, SD, or PD.	Up to 46 months
Number of HER2-Negative Participants at Baseline With and Without Seroconversion to a Status of HER2 Positive	Participants who had a HER2-negative tumor status based on baseline tissue with baseline serum HER2 ECD values =<15 ng/mL but later had at least two consecutive serum HER2 ECD values >15 ng/mL experienced seroconversion.	Up to 46 months
Time to Seroconversion for Participants Who Were HER2 Negative at Baseline But Became HER2 Positive	Time to seroconversion was defined as the time from the date of randomization until the first instance of serum HER2 (>15 ng/mL) on two consecutive occasions.	Up to 46 months
Number of Participants With the Indicated Expression of Tumor by Epidermal Growth Factor Receptor (ErbB1/HER1/EGFR) at Baseline	EGFR is a cell surface receptor tyrosine kinase expressed in certain types of tumors. Depending upon the staining intensity, EGFR was graded as follows: 0=absence of membrane staining above background in all tumor cells; EGFR-positive=staining is defined as any IHC staining of tumor cell membranes above background level, whether it is complete or incomplete circumferential staining (1+, 2+, 3+).	Baseline

Collaborators and Investigators

• Sponsor: Novartis Pharmaceuticals

Publications and helpful links

General Publications

• Wedam SB, Beaver JA, Amiri-Kordestani L, Bloomquist E, Tang S, Goldberg KB, Sridhara R, Ibrahim A, Kim G, Kluetz P, McKee A, Pazdur R. US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments. J Clin Oncol. 2018 Apr 20;36(12):1225-1231. doi: 10.1200/JCO.2017.74.6917. Epub 2018 Mar 9.
• Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009 Nov 20;27(33):5538-46. doi: 10.1200/JCO.2009.23.3734. Epub 2009 Sep 28.
• Prat A, Cheang MC, Galvan P, Nuciforo P, Pare L, Adamo B, Munoz M, Viladot M, Press MF, Gagnon R, Ellis C, Johnston S. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. JAMA Oncol. 2016 Oct 1;2(10):1287-1294. doi: 10.1001/jamaoncol.2016.0922.
• Schwartzberg LS, Franco SX, Florance A, O'Rourke L, Maltzman J, Johnston S. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist. 2010;15(2):122-9. doi: 10.1634/theoncologist.2009-0240. Epub 2010 Feb 15. Erratum In: Oncologist. 2010;15(3):327. Schwarzberg, Lee S [corrected to Schwartzberg, Lee S].
• Sherrill B, Amonkar MM, Sherif B, Maltzman J, O'Rourke L, Johnston S. Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. Oncologist. 2010;15(9):944-53. doi: 10.1634/theoncologist.2010-0012. Epub 2010 Aug 26.
• Finn RS, Press MF, Dering J, O'Rourke L, Florance A, Ellis C, Martin AM, Johnston S. Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res. 2014 Feb 1;20(3):736-43. doi: 10.1158/1078-0432.CCR-13-1260. Epub 2013 Nov 6.

Study record dates

Study Major Dates

• Study Start (Actual): December 9, 2003
• Primary Completion (Actual): June 3, 2008
• Study Completion (Actual): March 22, 2018

Study Registration Dates

• First Submitted: November 24, 2003
• First Submitted That Met QC Criteria: November 25, 2003
• First Posted (Estimate): November 26, 2003

Study Record Updates

• Last Update Posted (Actual): February 24, 2021
• Last Update Submitted That Met QC Criteria: February 8, 2021
• Last Verified: February 1, 2021

More Information

Terms related to this study

• Keywords: breast cancer; HER2; breast carcinoma; Lapatinib; Letrozole; ER; breast lump; HER2 positive metastatic breast cancer; breast cancer progression; breast cancer positive for human epidermal growth factor receptor 2; estrogen-receptor positive breast cancer
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Protein Kinase Inhibitors; Hormone Antagonists; Aromatase Inhibitors; Steroid Synthesis Inhibitors; Estrogen Antagonists; Letrozole; Lapatinib
• Other Study ID Numbers: EGF30008; CLAP016A2308 (Other Identifier: Novartis); 2004-003928-35 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

IPD Plan Description

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No